Efficacy Study of the Effect of Budesonide on Emphysema

AstraZeneca240 enrolled

Overview

To assess the effect of up to 4 years treatment with budesonide on progression of emphysema in patients with Chronic Obstructive Lung Disease.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

240

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Pulmicort (budesonide) TurbuhalerDRUG

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical Chronic Obstructive Pulmonary Disease diagnosis * smoker Exclusion Criteria: * No exacerbation within the last 30 days * no long term use of oral corticosteroids

Locations (1)

Research Site

Gentofte Municipality, Denmark

Outcomes

Primary Outcomes

The primary variable in the study was change in lung density measured by Computed Tomography annually.

Secondary Outcomes

Decline in lung Function (FEV1) and exacerbation rate were measured biannually and decline in diffusion capacity (TLCO) annually.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.